Taiwan
· Delayed Price · Currency is TWD TaiRx Company Description
TaiRx, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases.
The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial; and Rexis, an add-on injection therapy that is in Phase III clinical trials to treat patients with sepsis.
Its pre-clinical products comprise TRX-711 that is used to treat secondary hyperparathyroidism; TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis.
The company also offers Zelnite, a drug that helps in patient’s blood Se level and immune system; and focuses on development of the nodal diagnostic devices and anti-body drugs.
TaiRx, Inc. was founded in 2011 and is based in Taipei City, Taiwan.
| Country | Taiwan |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Du-Shieng Chien |
Contact Details
Address: No. 66, San-Chung Road Taipei City, 11502 Taiwan | |
| Phone | 886 2 2653 5007 |
| Website | trx.com.tw |
Stock Details
| Ticker Symbol | 6580 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006580004 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Du-Shieng Chien | Chief Executive Officer |
| Huang Shiqi | Chief Financial Officer |